Clinical Trial Update: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing HRS9531 to semaglutide as add-on therapy to metformin (with or without SGLT2 inhibitors) in adults with type 2 diabetes; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• HRS9531
• semaglutide (semaglutide)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED